Page 131 - Read Online

Musumeci et al. J Transl Genet Genom 2020;4:221-37 I https://doi.org/10.20517/jtgg.2020.22 Page 235

11778 mitochondrial DNA mutation. Neurology 1999;53:1787-93.
58. Vital C, Julien J, Martin-Negrier ML, Lagueny A, Ferrer X, et al. Parkinsonism in a patient with Leber hereditary optic neuropathy
(LHON). Rev Neurol 2015;171:679-80.
59. Tzoulis C, Schwarzlmüller T, Biermann M, Haugarvoll K, Bindoff LA. Mitochondrial DNA homeostasis s essential for nigrostriatal
integrity. Mitochondrion 2016;28:33-7.
60. Luoma P, Melberg A, Rinne JO, Kaukonen JA, Nupponen NN, et al. Parkinsonism, premature menopause and mitochondrial DNA
polymerase gamma mutations: clinical and molecular genetic study. Lancet 2004;364:875-82.
61. Baloh RH, Salavaggione E, Milbrandt J, Pestronk A. Familial parkinsonism and ophthalmoplegia from a mutation in the mitochondrial
DNA helicase twinkle. Arch Neurol 2007;64:998-1000.
62. Carelli V, Musumeci O, Caporali L, Zanna C, La Morgia C, et al. Syndromic parkinsonism and dementia associated with OPA1 missense
mutations. Ann Neurol 2015;78:21-38.
63. Garone C, Rubio JC, Calvo SE, Naini A, Tanji K, et al. MPV17 mutations causing adult-onset multisystemic disorder with multiple
mitochondrial DNA deletions. Arch Neurol 2012;69:1648-51.
64. Van Maldergem L, Besse A, De Paepe B, Blakely EL, Appadurai V, et al. POLG2 deficiency causes adult-onset syndromic sensory
neuropathy, ataxia and parkinsonism. Ann Clin Transl Neurol 2016;4:4-14.
65. Mancuso M, Filosto M, Oh SJ, DiMauro S. A novel polymerase gamma mutation in a family with ophthalmoplegia, neuropathy, and
Parkinsonism. Arch Neurol 2004;61:1777-9.
66. Davidzon G, Greene P, Mancuso M, Klos KJ, Ahlskog JE, et al. Early-onset familial parkinsonism due to POLG mutations. Ann Neurol
2006;59:859-62.
67. Betts-Henderson J, Jaros E, Krishnan KJ, Perry RH, Reeve AK, et al. Alpha-synuclein pathology and Parkinsonism associated with
POLG1 mutations and multiple mitochondrial DNA deletions. Neuropathol Appl Neurobiol 2009;35:120-4.
68. Invernizzi F, Varanese S, Thomas A, Carrara F, Onofrj M, et al. Two novel POLG1 mutations in a patient with progressive external
ophthalmoplegia, levodopa-responsive pseudo-orthostatic tremor and parkinsonism. Neuromuscul Disord 2008;18:460-4.
69. Remes AM, Hinttala R, Kärppä M, Soini H, Takalo R, et al. Parkinsonism associated with the homozygous W748S mutation in the
POLG1 gene. Parkinsonism Relat Disord 2008;14:652-4.
70. Hudson G, Schaefer AM, Taylor RW, Tiangyou W, Gibson A, et al. Mutation of the linker region of the polymerase gamma-1 (POLG1)
gene associated with progressive external ophthalmoplegia and Parkinsonism. Arch Neurol 2007;64:553-7.
71. Synofzik M, Asmus F, Reimold M, Schöls L, Berg D. Sustained dopaminergic response of parkinsonism and depression in POLG-
associated parkinsonism. Mov Disord 2010;25:243-5.
72. Galassi G, Lamantea E, Invernizzi F, Tavani F, Pisano I, et al. Additive effects of POLG1 and ANT1 mutations in a complex
encephalomyopathy. Neuromuscul Disord 2008;18:465-70
73. Sato K, Yabe I, Yaguchi H, Nakano F, Kunieda Y, et al. Genetic analysis of two Japanese families with progressive external
ophthalmoplegia and parkinsonism. J Neurol 2011;258:1327-32.
74. Van Goethem G, Löfgren A, Dermaut B, Ceuterick C, Martin JJ, et al. Digenic progressive external ophthalmoplegia in a sporadic patient:
recessive mutations in POLG and C10orf2/Twinkle. Hum Mutat 2003;22:175-6.
75. Vandenberghe W, Van Laere K, Debruyne F, Van Broeckhoven C, Van Goethem G. Neurodegenerative parkinsonism and progressive
external ophthalmoplegia with a Twinkle mutation. Mov Disord 2009;24:308-9.
76. Kiferle L, Orsucci D, Mancuso M, Lo Gerfo A, Petrozzi L, et al. Twinkle mutation in an Italian family with external progressive
ophthalmoplegia and parkinsonism: a case report and an update on the state of art. Neurosci Lett 2013;556:1-4.
77. Brandon BR, Diederich NJ, Soni M, Witte K, Weinhold M, et al. Autosomal dominant mutations in POLG and C10orf2: association with
late onset chronic progressive external ophthalmoplegia and Parkinsonism in two patients. J Neurol 2013;260:1931-3.
78. De la Casa-Fages B, Fernández-Eulate G, Gamez J, Barahona-Hernando R, Morís G, García-Barcina M, et al. Parkinsonism and spastic
paraplegia type 7: expanding the spectrum of mitochondrial Parkinsonism. Mov Disord 2019;34:1547-61.
79. Wilcox RA, Churchyard A, Dahl HH, Hutchinson WM, Kirbi DM, et al. Levodopa response in Parkinsonism with multiple mitochondrial
DNA deletions. Mov Disord 2007;22:1020-3.
80. Chalmers RM, Brockington M, Howard RS, Lecky BR, Morgan-Hughes JA, et al. Mitochondrial encephalopathy with multiple
mitochondrial DNA deletions: a report of two families and two sporadic cases with unusual clinical and neuropathological features. J
Neurol Sci 1996;143:45.
81. Siciliano G, Mancuso M, Ceravolo R, Lombardi V, Iudice A, et al. Mitochondrial DNA rearrangements in young onset parkinsonism: two
case reports. J Neurol Neurosurg Psychiatry 2001;71:685-7.
82. Casali C, Bonifati V, Santorelli FM, Casari G, Fortini D, et al. Mitochondrial myopathy, parkinsonism, and multiple mtDNA deletions in
a Sephardic Jewish family. Neurology 2001;56:802-5.
83. Lehmann Urban D, Motlagh Scholle L, Alt K, Ludolph AC, Rosenbohm A. Camptocormia as a novel phenotype in a
heterozygous POLG2 mutation. Diagnostics 2020;10:E68.
84. Ma L, Mao W, Xu E, Cai Y, Wang C, et al. Novel POLG mutation in a patient with early-onset parkinsonism, progressive external
ophthalmoplegia and optic atrophy Int J Neurosci 2019;130:319-21.
85. Giannoccaro MP, La Morgia C, Rizzo G, Carelli V. Mitochondrial DNA and primary mitochondrial dysfunction in Parkinson’s
disease. Mov Disord 2017;32:346-63.
86. Jiang X, Jin T, Zhang H, Miao J, Zhao X, et al. Current progress of mitochondrial quality control pathways underlying the pathogenesis
of Parkinson’s disease. Oxid Med Cell Longev 2019:4578462.